# The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

> **NCT06993766** · — · NOT_YET_RECRUITING · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed B-ALL
- CAR T-cells
- CD19-directed CAR T-cell Therapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06993766
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-20
- **Primary completion:** 2030-05-01
- **Final completion:** 2030-05-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06993766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06993766, "The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06993766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*